Gain-of-function CaSR mutations result in autosomal dominant hypocalcemia, whereas loss-of-function CaSR mutations cause severe neonatal primary hyperparathyroidism (Hendy et al., 2009; Ward et al., 2012; Hannan et al., 2018). This evidence concerns the gene CASR and primary hyperparathyroidism.